AOD 9604

Clinical claims and research

During the 90s, researchers from Monash University in Australia found that growth hormone (GH) was responsible for controlling the effects of AOD 9604. In clinical trials, the overall goal of the research was to find an anti-obesity drug that could burn fats without promoting muscle growth. In doing so, researchers found that AOD 9604 had the ability to：
Decrease the development of new fat.
Regulate the body's metabolism.
Stimulate the release of fats from fat cells.
Help treat osteoarthritis and bone repair.
In other clinical trials, patients were shown to experience less fatigue and had more endurance to exercise. Patients suffering from obesity also reported feeling less hungry and were found to eat less when using AOD 9604.

Regulations

The U.S. Food & Drug Administration recently assigned Human GRAS status to AOD 9604, which is listed under the Generally Recognized As Safe (GRAS) program. This designation identifies any food additive as safe when used as intended, per the Federal Food, Drug, and Cosmetic Act. This peptide is extremely safe, and there are no known health risks associated with AOD 9604 injections, especially when compared to traditional hormone-based weight loss treatments.